Mix of In-Office, Telehealth Visits Safe for Prenatal Care
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, July 18, 2023 -- A multimodal prenatal health care model that combines in-office and telemedicine visits is safe and associated with similar maternal and newborn outcomes as exclusive in-office visits, according to a study published online July 18 in JAMA Network Open.
Assiamira Ferrara, M.D., Ph.D., from Kaiser Permanente Northern California in Oakland, and colleagues evaluated whether prenatal health care delivered by a multimodal model of in-office and telemedicine visits during the COVID-19 pandemic resulted in similar maternal and newborn health outcomes to prepandemic in-office health care.
The researchers found that among 151,464 individuals who delivered a live birth or stillbirth, the mean number of total prenatal visits was similar among those who were unexposed (birth delivery: July 1, 2018, to Feb. 29, 2020), partially exposed (birth delivery: March 1, 2020, to Dec. 5, 2020), and fully exposed (birth delivery: Dec. 6, 2020, to Oct. 31, 2021) to the multimodal prenatal health care model. Across the time periods, neonatal intensive care unit admissions were 9.2, 8.3, and 8.6 percent, respectively. There were no clinically relevant changes observed over time in the risk for preeclampsia and eclampsia, severe maternal morbidity, cesarean delivery, preterm birth, or secondary outcomes.
"These findings suggest that a multimodal prenatal health care model combining in-office and telemedicine visits performed adequately compared with in-office only prenatal health care, supporting its continued use after the pandemic," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.